Skip to main content
Erschienen in: Endocrine 1/2015

01.05.2015 | Endocrine Genetics/Epigenetics

Early onset acromegaly associated with a novel deletion in CDKN1B 5′UTR region

verfasst von: Silvia Sambugaro, Mauro Di Ruvo, Maria Rosaria Ambrosio, Natalia S. Pellegata, Mariaenrica Bellio, Alessandra Guerra, Mattia Buratto, Maria Pia Foschini, Federico Tagliati, Ettore degli Uberti, Maria Chiara Zatelli

Erschienen in: Endocrine | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Genetic alterations frequently are involved in the development of a pituitary adenoma in young age. We here characterize the functional role of a deletion in CDKN1B 5′-UTR region (c.-29_-26delAGAG) identified in an acromegalic patient that developed a growth hormone in pituitary adenoma during childhood. Our results show that the identified novel heterozygous deletion in the CDKN1B 5′-UTR region associates with a reduction in CDKN1B mRNA levels, a predicted altered secondary mRNA structure, and a reduced CDKN1B 5′-UTR transcriptional activity in vitro. The patient displayed loss of heterozygosity in the same CDKN1B 5′-UTR region at tissue level and the 5′UTR region containing the deleted sequence encompasses a GRE. These findings indicate that the identification of functional alterations of newly discovered genetic derangements need to be fully characterized and always correlated with the clinical manifestations.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat A.F. Daly, M. Rixhon, C. Adam, A. Dempegioti, M.A. Tichomirowa, A. Beckers, High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J. Clin. Endocrinol. Metab. 91, 4769–4775 (2006)CrossRefPubMed A.F. Daly, M. Rixhon, C. Adam, A. Dempegioti, M.A. Tichomirowa, A. Beckers, High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J. Clin. Endocrinol. Metab. 91, 4769–4775 (2006)CrossRefPubMed
2.
Zurück zum Zitat A. Fernandez, N. Karavitaki, J.A. Wass, Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin. Endocrinol. (Oxf) 72, 377–382 (2010)CrossRef A. Fernandez, N. Karavitaki, J.A. Wass, Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin. Endocrinol. (Oxf) 72, 377–382 (2010)CrossRef
3.
Zurück zum Zitat N.S. Pellegata, L. Quintanilla-Martinez, H. Siggelkow, E. Samson, K. Bink, H. Hofler, F. Fend, J. Graw, M.J. Atkinson, Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc. Natl. Acad. Sci. 103, 15558–15563 (2006)CrossRefPubMedCentralPubMed N.S. Pellegata, L. Quintanilla-Martinez, H. Siggelkow, E. Samson, K. Bink, H. Hofler, F. Fend, J. Graw, M.J. Atkinson, Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc. Natl. Acad. Sci. 103, 15558–15563 (2006)CrossRefPubMedCentralPubMed
4.
Zurück zum Zitat M. Lee, N.S. Pellegata, Multiple endocrine neoplasia syndromes associated with mutation of p27. J. Endocrinol. Invest. 36(9), 781–787 (2013)PubMed M. Lee, N.S. Pellegata, Multiple endocrine neoplasia syndromes associated with mutation of p27. J. Endocrinol. Invest. 36(9), 781–787 (2013)PubMed
5.
Zurück zum Zitat M.A. Tichomirowa, M. Lee, A. Barlier, A.F. Daly, I. Marinoni, M.L. Jaffrain-Rea, L.A. Naves, P. Rodien, V. Rohmer, F.R. Faucz, P. Caron, B. Estour, P. Lecomte, F. Borson-Chazot, A. Penfornis, M. Yaneva, M. Guitelman, E. Castermans, C. Verhaege, J.L. Wémeau, A. Tabarin, C. Fajardo Montañana, B. Delemer, V. Kerlan, J.L. Sadoul, C. Cortet Rudelli, F. Archambeaud, S. Zacharieva, M. Theodoropoulou, T. Brue, A. Enjalbert, V. Bours, N.S. Pellegata, A. Beckers, Cyclin-dependent kinase inhibitor 1B (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenoma kindreds. Endocr. Relat. Cancer 19(3), 233–241 (2012)CrossRefPubMed M.A. Tichomirowa, M. Lee, A. Barlier, A.F. Daly, I. Marinoni, M.L. Jaffrain-Rea, L.A. Naves, P. Rodien, V. Rohmer, F.R. Faucz, P. Caron, B. Estour, P. Lecomte, F. Borson-Chazot, A. Penfornis, M. Yaneva, M. Guitelman, E. Castermans, C. Verhaege, J.L. Wémeau, A. Tabarin, C. Fajardo Montañana, B. Delemer, V. Kerlan, J.L. Sadoul, C. Cortet Rudelli, F. Archambeaud, S. Zacharieva, M. Theodoropoulou, T. Brue, A. Enjalbert, V. Bours, N.S. Pellegata, A. Beckers, Cyclin-dependent kinase inhibitor 1B (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenoma kindreds. Endocr. Relat. Cancer 19(3), 233–241 (2012)CrossRefPubMed
6.
Zurück zum Zitat G. Occhi, G. Trivellin, F. Ceccato, P. De Lazzari, G. Giorgi, S. Demattè, F. Grimaldi, R. Castello, M.V. Davì, G. Arnaldi, L. Salviati, G. Opocher, F. Mantero, C. Scaroni, Prevalence of AIP mutations in a large series of sporadic Italian acromegalic patients and evaluation of CDKN1B status in acromegalic patients with multiple endocrine neoplasia. Eur J Endocrinol. 163(3), 369–376 (2010)CrossRefPubMed G. Occhi, G. Trivellin, F. Ceccato, P. De Lazzari, G. Giorgi, S. Demattè, F. Grimaldi, R. Castello, M.V. Davì, G. Arnaldi, L. Salviati, G. Opocher, F. Mantero, C. Scaroni, Prevalence of AIP mutations in a large series of sporadic Italian acromegalic patients and evaluation of CDKN1B status in acromegalic patients with multiple endocrine neoplasia. Eur J Endocrinol. 163(3), 369–376 (2010)CrossRefPubMed
8.
Zurück zum Zitat S.K. Agarwal, C.M. Mateo, S.J. Marx, Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. J. Clin. Endocrinol. Metab. 94, 1826–1834 (2009)CrossRefPubMedCentralPubMed S.K. Agarwal, C.M. Mateo, S.J. Marx, Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. J. Clin. Endocrinol. Metab. 94, 1826–1834 (2009)CrossRefPubMedCentralPubMed
9.
Zurück zum Zitat G. Occhi, D. Regazzo, G. Trivellin, F. Boaretto, D. Ciato, S. Bobisse, S. Ferasin, F. Cetani, E. Pardi, M. Korbonits, N.S. Pellegata, V. Sidarovich, A. Quattrone, G. Opocher, F. Mantero, C. Scaroni, A novel mutation in the upstream open reading frame of the CDKN1B gene causes a MEN4 phenotype. PLoS Genet. 9(3), E1003350 (2013)CrossRefPubMedCentralPubMed G. Occhi, D. Regazzo, G. Trivellin, F. Boaretto, D. Ciato, S. Bobisse, S. Ferasin, F. Cetani, E. Pardi, M. Korbonits, N.S. Pellegata, V. Sidarovich, A. Quattrone, G. Opocher, F. Mantero, C. Scaroni, A novel mutation in the upstream open reading frame of the CDKN1B gene causes a MEN4 phenotype. PLoS Genet. 9(3), E1003350 (2013)CrossRefPubMedCentralPubMed
10.
Zurück zum Zitat M. Georgitsi, A. Raitila, A. Karhu, R.B. van der Luijt, C.M. Aalfs, T. Sane et al., Germline cdkn1b/p27kip1 mutation in multiple endocrine neoplasia. J. Clin. Endocrinol. Metab. 92(8), 3321–3355 (2007)CrossRefPubMed M. Georgitsi, A. Raitila, A. Karhu, R.B. van der Luijt, C.M. Aalfs, T. Sane et al., Germline cdkn1b/p27kip1 mutation in multiple endocrine neoplasia. J. Clin. Endocrinol. Metab. 92(8), 3321–3355 (2007)CrossRefPubMed
11.
Zurück zum Zitat S. Molatore, I. Marinoni, M. Lee, E. Pulz, M.R. Ambrosio et al., A novel germline CDKN1B mutation causing multiple endocrine tumors: clinical, genetic and functional characterization. Hum. Mutat. 31, E1825–E1835 (2010)CrossRefPubMedCentralPubMed S. Molatore, I. Marinoni, M. Lee, E. Pulz, M.R. Ambrosio et al., A novel germline CDKN1B mutation causing multiple endocrine tumors: clinical, genetic and functional characterization. Hum. Mutat. 31, E1825–E1835 (2010)CrossRefPubMedCentralPubMed
12.
Zurück zum Zitat S. Takeuchi, H.P. Koeffler, D.R. Hinton, I. Miyoshi, S. Melmed, I. Shimon, Mutation and expression analysis of the cyclindependent kinase inhibitor gene p27/Kip1 in pituitary tumors. J. Endocrinol. 157, 337–341 (1998)CrossRefPubMed S. Takeuchi, H.P. Koeffler, D.R. Hinton, I. Miyoshi, S. Melmed, I. Shimon, Mutation and expression analysis of the cyclindependent kinase inhibitor gene p27/Kip1 in pituitary tumors. J. Endocrinol. 157, 337–341 (1998)CrossRefPubMed
13.
Zurück zum Zitat D. Malanga, S. De Gisi, M. Riccardi, M. Scrima, C. De Marco, M. Robledo, G. Viglietto, Functional characterization of a rare germline mutation in the gene encoding the cyclin-dependent kinase inhibitor p27Kip1 (CDKN1B) in a Spanish patient with multiple endocrine neoplasia-like phenotype. Eur. J. Endocrinol. 166, 551–560 (2012)CrossRefPubMed D. Malanga, S. De Gisi, M. Riccardi, M. Scrima, C. De Marco, M. Robledo, G. Viglietto, Functional characterization of a rare germline mutation in the gene encoding the cyclin-dependent kinase inhibitor p27Kip1 (CDKN1B) in a Spanish patient with multiple endocrine neoplasia-like phenotype. Eur. J. Endocrinol. 166, 551–560 (2012)CrossRefPubMed
14.
Zurück zum Zitat M.C. Zatelli, G. Trasforini, S. Leoni, G. Frigato, M. Buratto, F. Tagliati, R. Rossi, L. Cavazzini, E. Roti, E.C. degli Uberti, BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies. Eur. J. Endocrinol. 161(3), 467–473 (2009)CrossRefPubMed M.C. Zatelli, G. Trasforini, S. Leoni, G. Frigato, M. Buratto, F. Tagliati, R. Rossi, L. Cavazzini, E. Roti, E.C. degli Uberti, BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies. Eur. J. Endocrinol. 161(3), 467–473 (2009)CrossRefPubMed
15.
Zurück zum Zitat F. Tagliati, E. Gentilin, M. Buratto, D. Molè, E.C. degli Uberti, M.C. Zatelli, Magmas, a gene newly identified as overexpressed in human and mouse ACTH-secreting pituitary adenomas, protects pituitary cells from apoptotic stimuli. Endocrinology 151(10), 4635–4642 (2010)CrossRefPubMed F. Tagliati, E. Gentilin, M. Buratto, D. Molè, E.C. degli Uberti, M.C. Zatelli, Magmas, a gene newly identified as overexpressed in human and mouse ACTH-secreting pituitary adenomas, protects pituitary cells from apoptotic stimuli. Endocrinology 151(10), 4635–4642 (2010)CrossRefPubMed
16.
Zurück zum Zitat M.C. Zatelli, M. Minoia, D. Molè, V. Cason, F. Tagliati, A. Margutti, M. Bondanelli, M.R. Ambrosio, E. degli Uberti, Growth hormone excess promotes breast cancer chemoresistance. J. Clin. Endocrinol. Metab. 94(10), 3931–3938 (2009)CrossRefPubMed M.C. Zatelli, M. Minoia, D. Molè, V. Cason, F. Tagliati, A. Margutti, M. Bondanelli, M.R. Ambrosio, E. degli Uberti, Growth hormone excess promotes breast cancer chemoresistance. J. Clin. Endocrinol. Metab. 94(10), 3931–3938 (2009)CrossRefPubMed
17.
Zurück zum Zitat L. Hengst, S.I. Reed, Translational control of p27Kip1 accumulation during the cell cycle. Science 271, 1861–1864 (1996)CrossRefPubMed L. Hengst, S.I. Reed, Translational control of p27Kip1 accumulation during the cell cycle. Science 271, 1861–1864 (1996)CrossRefPubMed
18.
Zurück zum Zitat M. Pagano, S.W. Tam, A.M. Theodoras, P. Beer-Romero, G. Del Sal, V. Chau, P.R. Yew, G.F. Draetta, M. Rolfe, Role of the ubiquitin—proteasome pathway in regulating abundance of the cyclindependent kinase inhibitor p27. Science 269, 682–685 (1995)CrossRefPubMed M. Pagano, S.W. Tam, A.M. Theodoras, P. Beer-Romero, G. Del Sal, V. Chau, P.R. Yew, G.F. Draetta, M. Rolfe, Role of the ubiquitin—proteasome pathway in regulating abundance of the cyclindependent kinase inhibitor p27. Science 269, 682–685 (1995)CrossRefPubMed
19.
Zurück zum Zitat G. Chiappetta, C. De Marco, A. Quintiero, D. Califano, S. Gherardi, D. Malanga, M. Scrima, C. Montero-Conde, L. Cito, M. Monaco, M.L. Motti, R. Pasquinelli, V. Agosti, M. Robledo, A. Fusco, G. Viglietto, Overexpression of the S-phase kinase-associated protein 2 in thyroid cancer. Endocr. Relat. Cancer 14, 405–420 (2007)CrossRefPubMed G. Chiappetta, C. De Marco, A. Quintiero, D. Califano, S. Gherardi, D. Malanga, M. Scrima, C. Montero-Conde, L. Cito, M. Monaco, M.L. Motti, R. Pasquinelli, V. Agosti, M. Robledo, A. Fusco, G. Viglietto, Overexpression of the S-phase kinase-associated protein 2 in thyroid cancer. Endocr. Relat. Cancer 14, 405–420 (2007)CrossRefPubMed
20.
Zurück zum Zitat A. Peiretti, N. Baghdassarian, L.M. Gerland, P. Ffrench, P.A. Bryon, J.P. Magaud et al., CDK2 is involved in the S-phase lengthening induced by glucocorticoids in normal human lymphocytes. Eur. J. Cell Biol. 82, 253–261 (2003)CrossRefPubMed A. Peiretti, N. Baghdassarian, L.M. Gerland, P. Ffrench, P.A. Bryon, J.P. Magaud et al., CDK2 is involved in the S-phase lengthening induced by glucocorticoids in normal human lymphocytes. Eur. J. Cell Biol. 82, 253–261 (2003)CrossRefPubMed
21.
Zurück zum Zitat J. Slingerland, M. Pagano, Regulation of the cdk inhibitor p27 and its deregulation in cancer. J. Cell. Physiol. 183(1), 10–17 (2000)CrossRefPubMed J. Slingerland, M. Pagano, Regulation of the cdk inhibitor p27 and its deregulation in cancer. J. Cell. Physiol. 183(1), 10–17 (2000)CrossRefPubMed
22.
Zurück zum Zitat M.K. Kullmann, C. Grubbauer, K. Goetsch, H. Jäkel, S.R. Podmirseg, A. Trockenbacher, C. Ploner, A.C. Cato, C. Weiss, R. Kofler, L. Hengst, The p27-Skp2 axis mediates glucocorticoid-induced cell cycle arrest in T-lymphoma cells. Cell Cycle 12(16), 2625–2635 (2013)CrossRefPubMedCentralPubMed M.K. Kullmann, C. Grubbauer, K. Goetsch, H. Jäkel, S.R. Podmirseg, A. Trockenbacher, C. Ploner, A.C. Cato, C. Weiss, R. Kofler, L. Hengst, The p27-Skp2 axis mediates glucocorticoid-induced cell cycle arrest in T-lymphoma cells. Cell Cycle 12(16), 2625–2635 (2013)CrossRefPubMedCentralPubMed
Metadaten
Titel
Early onset acromegaly associated with a novel deletion in CDKN1B 5′UTR region
verfasst von
Silvia Sambugaro
Mauro Di Ruvo
Maria Rosaria Ambrosio
Natalia S. Pellegata
Mariaenrica Bellio
Alessandra Guerra
Mattia Buratto
Maria Pia Foschini
Federico Tagliati
Ettore degli Uberti
Maria Chiara Zatelli
Publikationsdatum
01.05.2015
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 1/2015
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-015-0540-y

Weitere Artikel der Ausgabe 1/2015

Endocrine 1/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.